Reasons to Retain Chemed Stock in Your Portfolio Now
Investors feel optimistic about CHE's strong growth prospects in the VITAS business. Yet, unfavorable macroeconomic conditions are concerning.
Final Trades: Exxon, Chemed, Las Vegas Sands and the IEO
The Investment Committee give you their top stocks to watch for the second half.
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock?
Chemed Remains A Buy On Long-Term Economics
Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business.
Here's Why Chemed (CHE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Ways to Play the Long-Term Care Crisis in 2024
Morningstar.com published an interesting piece in July about the long-term health care crisis. It pointed out that Americans paid out $245 billion for long term care to paid caregivers, nursing homes and other forms of paid assistance.
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Why Growth Investors Shouldn't Overlook Chemed (CHE)
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Chemed (CHE) Misses Q2 Earnings and Revenue Estimates
Chemed (CHE) came out with quarterly earnings of $5.47 per share, missing the Zacks Consensus Estimate of $5.54 per share. This compares to earnings of $4.71 per share a year ago.
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
